TITLE

Deals roundup

PUB. DATE
May 2010
SOURCE
Medical Device Daily;5/26/2010, Vol. 14 Issue 101, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports that Valocor Therapeutics has acquired and licensed certain dermatology therapeutic programs from QLT.
ACCESSION #
50993786

 

Related Articles

  • With $42M Series A, Dermira Amasses Dermatology Assets. Morrison, Trista // BioWorld Today;10/24/2011, Vol. 22 Issue 206, p1 

    The article reports on the 42 million dollar Series A financing raised by Dermira Inc. which it used to acquire dermatology assets including Valocor Therapeutics Inc. Tom Wiggans, chief executive officer (CEO) of Dermira, mentions three factors that fueled interest in the dermatology sector,...

  • QLT GETS POSITIVE OPINIONS FOR QLT091001 AS ORPHAN DRUG.  // Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p2 

    The article provides information on the oral synthetic retinoid, QLT091001, a drug developed by QLT Inc. in Vancouver, British Columbia, for the treatment of two diseases of inherited blindness which include the leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). It reports that the...

  • QLT: Combo AMD Therapy Cuts Retreatments.  // Review of Ophthalmology;Jul2010, Vol. 17 Issue 7, p7 

    The article offers information on the release of the 24-month results of QLT Inc.'s Phase II Radical study in patients with age-related macular degeneration (AMD). It notes that the study intends to compare the retreatment rates of Visudyne combined with Lucentis and Lucentis monotherapy while...

  • Dermira Takes in $35M in Funding to Enhance Pipeline. Powers, Marie // BioWorld Today;6/12/2013, Vol. 24 Issue 112, p1 

    The article reports on the funding secured by biotechnology company Dermira Inc. from a Series B financing that included leading Japanese dermatology company Maruho Co. Ltd. Dermira entered the dermatology market in 2011 with lemuteporfin (LTS) as its leading product candidate, which is...

  • 'Massive' Consolidation Creates Opportunity. Powers, Marie // BioWorld Today;6/12/2013, Vol. 24 Issue 112, p7 

    The article reports on the funding secured by biotechnology company Dermira Inc. from a Series B financing that included leading Japanese dermatology company Maruho Co. Ltd. Dermira entered the dermatology market in 2011 with lemuteporfin (LTS) as its leading product candidate, which is...

  • Dermira Announces a $42m Series A Financing to Fund Therapeutic Advances in Dermatology.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p505 

    The article reports on the 42 million dollar Series A financing of Redwood City, California-based private company Dermira Inc. in 2011. It notes that the financing is aimed at supporting the acquisition, development and commercialization of therapeutics in dermatology. It also mentions the...

  • Valocor says 'Beat It' to Acne, Atopic Dermatitis and Vitiligo. Shaffer, Catherine // BioWorld Today;8/13/2010, Vol. 21 Issue 156, p1 

    The article discusses plans by Valocor Therapeutics Inc. of Vancouver, British Columbia to develop new dermatology treatments. The company acquired licenses for therapeutic dermatology compounds from QLT Inc. including the clinical-stage topical photodynamic therapy lemuteporfin for acne and...

  • Europe's license law.  // Chemical Week;8/2/1995, Vol. 157 Issue 4, p33 

    Reports on the European Commission's renewal of two laws on technology licensing arrangements until the end of 1995.

  • LMDS explosion. Levine, Shira // Telephony;3/17/97, Vol. 232 Issue 11, p6 

    Discusses the limitation of obtaining licenses of the local exchange carriers (LECs) for the LMDS spectrum. Activation of cable as non-video competitor and telephony as video competitor; Contradiction of the order to the intents of Telecommunications Reform Act; Analysis on the amortization of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics